Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MDH1 | P40925 | 1/20 | 0.49 |
| ▸ | MDH2 | P40926 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013052 | 0.94 | MAPT (0.62) | MAPTKMT2AKDM4ETP53SMPD1 | |
| SCHEMBL1015775 | 0.94 | MAPT (0.62) | MAPTKMT2AKDM4ETP53SMPD1 | |
| SCHEMBL17835716 | 0.88 | SMPD1 (0.62) | MAPTKMT2AKDM4ESMPD1L3MBTL1 | |
| SCHEMBL9361024 | 0.88 | MAPT (0.49) | MAPTKMT2AKDM4EHTTTP53 | |
| SCHEMBL20982560 | 0.87 | MAPT (0.56) | MAPTKMT2AKDM4EHTTMDH1 | |
| SCHEMBL14391927 | 0.87 | CA12 (0.57) | MAPTKMT2AKDM4EHTTTP53 | |
| SCHEMBL17129602 | 0.87 | L3MBTL1 (0.57) | MAPTKMT2AKDM4EHTTMDH1 | |
| SCHEMBL25314236 | 0.87 | TDP1 (0.57) | MAPTKMT2AKDM4EHTTMDH1 | |
| SCHEMBL263238 | 0.86 | HSD17B2 (0.57) | MAPTKDM4ETP53TDP1L3MBTL1 | |
| SCHEMBL1345863 | 0.86 | MAPT (0.51) | MAPTKMT2AKDM4EHTTMDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343950-B2 | Cell surface tyrosine receptor kinase inhibitors; pyrogen-free; lung cancer; benign prostatic hyperplasia | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-7872014-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008076949-A2 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | ALK, MALT1, BCL6 | MAPT 2184/4885KMT2A 583/4885KDM4E 627/4885 |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | MAPT 2632/4885KMT2A 1929/4885KDM4E 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.